Loading clinical trials...
Loading clinical trials...
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Conditions
Interventions
PV-10 (10% rose bengal disodium)
Dacarbazine, temozolomide or talimogene laherparepvec
Locations
23
United States
Sharp Memorial Hospital - Clinical Oncology Research
San Diego, California, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Washington University School of Medicine - Dermatology
St Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Atlantic Health System
Morristown, New Jersey, United States
Start Date
April 1, 2015
Primary Completion Date
April 1, 2019
Completion Date
September 1, 2019
Last Updated
January 19, 2022
NCT05039801
NCT06391099
NCT06673095
NCT06999980
NCT07230613
NCT05588453
Lead Sponsor
Provectus Biopharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions